Healthcare Machine Learning5 min reading time

SimBioSys Wins FDA Clearance for Breast Cancer Recurrence AI Tool

Unite.AIPublished 3 hours ago

SimBioSys received FDA 510(k) clearance for TumorSight Risk, an AI tool that predicts 5- and 10-year breast cancer recurrence risk using MRI, pathology, and clinical data for HR-positive, HER2-negative breast cancer patients.

#breast-cancer-prognosis #simbiosys #tumorsight-risk #u-s-food-and-drug-administration

SimBioSys Wins FDA Clearance for Breast Cancer Recurrence AI Tool

More in Healthcare

AstraZeneca Strikes Up to $1.5 Billion AI Drug Discovery Deal With Insitro

Dyson CameraJet Review: $500 AI Toothbrush Has Reliability, Water Issues

Spatiotemporal AI-based modeling of gene regulation and variant effects in the developing human brain using Seal